Update on glioblastoma trial involving ANKTIVA coming May 21
This could be huge news if the results are positive.
Simon Khagi is the principal investigator on ImmunityBio’s recurrent/progressive glioblastoma trial involving ANKTIVA / N-803, PD-L1 t-haNK NK-cell therapy, and bevacizumab, with some arms involving TTFields / Optune Gio. The NCI trial listing says the trial is active and describes a phase 2 plus phase 2B design for recurrent or progressive glioblastoma.
The big update is from January 23, 2026: ImmunityBio reported that in its phase 2 recurrent GBM data, median overall survival had not yet been reached. OncLive summarized that this was in the efficacy-evaluable group of 14 patients, with 19 of 23 total enrolled patients alive at the data cutoff, at a median follow-up of about 6 months.
Khagi’s quoted interpretation was notably strong: he said recurrent GBM typically has median overall survival of about 6 to 9 months, and that seeing durable responses and manageable safety without chemotherapy could represent a “paradigm change.” That said, these are still early, small-sample, not-yet-definitive clinical data, not proof of a cure.
Looks like the next real public numbers are likely May 21, 2026, or during ASCO May 29 to June 2, 2026 with Simon Khagi as first author/presenter for ANKTIVA / NAI plus PD-L1 t-haNK and bevacizumab in glioblastoma.
ASCO says the majority of abstracts are released May 21, 2026 at 5:00 PM ET, and the annual meeting runs May 29 to June 2, 2026 in Chicago. So the abstract may show updated numbers on May 21, with fuller poster/presentation details during the meeting.